Differentiating pluripotent stem cells with CDX2, SB431542, Wnt3a, and EGF overcomes low enzyme expression in standard models.
Standardized marker panels select H2Stem Cells to resolve donor shortages and inconsistent engraftment in liver disease therapy.
A synthetic fetal liver organoid expands hematopoietic stem cells using genetically modified cell populations.
A stem cell culture method forms functional tissue clusters by optimizing mesenchymal and endothelial cell ratios within defined recess volumes.
Small molecule reagents replace costly protein growth factors to enable scalable, cost-effective liver organoid production.
Synchronizing iPS cell differentiation overcomes donor variability and limited growth capacity to form stable organ primordia.